PRAX (Praxis Precision Medicines) Short Interest


PRAX Praxis Precision Medicines Inc PRAX
38 GF Score
Price $322.67
GF Value $30.36
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Praxis Precision Medicines Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

PRAX vs KRYS, CYTK, NUVL: Short Interest Comparison

For the Biotechnology subindustry, Praxis Precision Medicines's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Praxis Precision Medicines Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Praxis Precision Medicines's Short Interest distribution charts can be found below:

* The bar in red indicates where Praxis Precision Medicines's Short Interest falls into.


PRAX
38GF Score
Praxis Precision Medicines Inc PRAX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Praxis Precision Medicines (PRAX) Overvalued in 2026?

Based on GuruFocus' analysis, Praxis Precision Medicines stock appears to be overvalued. The current stock price of $322.67 is trading 962.8% above its estimated GF Value™ of $30.36. GuruFocus considers Praxis Precision Medicines to be Significantly Overvalued.

Key valuation signals for PRAX:

  • Short Interest:
  • GF Value™: $30.36 vs. price of $322.67 (962.8% above fair value)
  • GF Score™: 38/100 with 1 warning sign

No single metric tells the full story. See the PRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Praxis Precision Medicines Business Description

Address 99 High Street, 30th Floor, Boston, MA, USA, 02110
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
38GF Score

Get the complete analysis for PRAX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$322.67
Price
$30.36
GF Value